12 completed, 4 active not recruiting, 2 terminated, 1 not yet recruiting. 10 Phase 2, 4 Phase 1, 4 Phase 3, 1 Not applicable.
Follow Synovitis, Pigmented Villonodular: new trials by email Literature Review of Synovitis, Pigmented Villonodular trials Research Report on Synovitis, Pigmented Villonodular
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor Pimicotinib, Tumor resection surgery - Tenosynovial Giant Cell Tumor, Diffuse | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 84 | 2027-10-01 | 2026-07-16 |
| Synovial Tissue as a Biomarker in the Management of Pigmented Villonodular Synovitis synovial biopsy - Synovitis Villonodular | Not applicable | Recruiting | Nantes University Hospital | 30 | 2026-09-01 | 2026-09-14 |
| Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) Emactuzumab, Placebo - TGCT | Phase 3 | Active not recruiting | SynOx Therapeutics Limited | 128 | 2024-10-09 | 2026-07-29 |
| Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) Pimicotinib(ABSK021), Placebo - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis | Phase 3 | Active not recruiting | Abbisko Therapeutics Co, Ltd | 94 | 2023-04-27 | 2026-05-04 |
| A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT AMB-05X - Pigmented Villonodular Synovitis, TGCT | Phase 2 | Completed | AmMax Bio, Inc. | 20 | 2023-01-26 | 2024-07-05 |
| Study of Vimseltinib for Tenosynovial Giant Cell Tumor Vimseltinib, Placebo - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis | Phase 3 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 123 | 2021-10-14 | 2026-03-20 |
| A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients AMB-05X - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis | Phase 2 | Terminated | AmMax Bio, Inc. | 4 | 2021-09-16 | 2024-05-24 |
| An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee AMB-05X - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis (PVNS) | Phase 2 | Completed | AmMax Bio, Inc. | 11 | 2021-05-25 | 2024-06-27 |
| A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan Pexidartinib - Tenosynovial Giant Cell Tumor | Phase 2 | Completed | Daiichi Sankyo Co., Ltd. | 9 | 2021-03-15 | 2026-06-24 |
| Screening of Specific Genes for Pigmented Villous Nodular Synovitis Arthroscopic synovectomy - Pigmented Villonodular Synovitis | Completed | Peking University Third Hospital | 60 | 2020-08-03 | 2021-07-08 | |
| Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics) Tolbutamide, Midazolam, Pexidartinib - Drug Interaction Potential | Phase 1 | Completed | Daiichi Sankyo | 32 | 2018-02-26 | 2021-05-14 |
| Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Vimseltinib - Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis | Phase 1 / Phase 2 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 120 | 2017-02-16 | 2026-06-25 |
| Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project Giant Cell Tumors | Completed | Daiichi Sankyo | 183 | 2016-11-18 | 2023-10-31 | |
| A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor PLX73086 - Solid Tumors, Tenosynovial Giant Cell Tumor | Phase 1 | Terminated | Plexxikon | 11 | 2016-02-01 | 2018-08-02 |
| Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor FPA008 - Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor | Phase 1 / Phase 2 | Completed | Five Prime Therapeutics, Inc. | 66 | 2015-06-01 | 2021-08-31 |
| Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) Pexidartinib, Placebo - Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath | Phase 3 | Completed | Daiichi Sankyo | 120 | 2015-05-11 | 2022-05-11 |
| MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) MCS110, Placebo - Pigmented Villonodular Synovitis, PVNS | Phase 2 | Completed | Novartis Pharmaceuticals | 36 | 2012-04-23 | 2021-01-05 |
| Clinical Study of Magnetic Resonance Imaging and Deep Learning of Joint Synovial Disease Synovitis diagnosis - Synovial Diseases, Pigmented Villonodular Synovitis | Completed | Peking University Third Hospital | 350 | 2012-01-01 | 2022-11-02 | |
| Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) Tasigna - Pigmented Villonodular Synovitis | Phase 2 | Completed | Centre Leon Berard | 50 | 2010-12-01 | 2013-04-16 |
| Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor nilotinib - Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor | Phase 2 | Completed | Andrew J. Wagner, MD, PhD | 17 | 2010-09-01 | 2026-02-20 |
Giant Cell Tumor of Tendon Sheath (12) · Synovitis (2) · Arthritis, Rheumatoid (1) · Giant Cell Tumors (1) · Gout (1) · Joint Diseases (1) · Neoplasms (1)
Muscular Diseases (20) · Musculoskeletal Diseases (20) · Neoplasms by Histologic Type (20) · Neoplasms, Connective Tissue (20) · Neoplasms, Connective and Soft Tissue (20) · Tendinopathy (20) · Giant Cell Tumors (19) · Joint Diseases (19) · Neoplasms (19) · Synovitis (18) · Giant Cell Tumor of Tendon Sheath (8) · Arthritis (1) · Autoimmune Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1)
pexidartinib (3) · nilotinib (2) · Bro protein, Drosophila (1) · Midazolam (1) · Tolbutamide (1) · cabiralizumab (1) · emactuzumab (1)
AmMax Bio, Inc. (3) · Daiichi Sankyo (3) · Deciphera Pharmaceuticals, LLC (2) · Peking University Third Hospital (2) · Abbisko Therapeutics Co, Ltd (1) · Andrew J. Wagner, MD, PhD (1) · Centre Leon Berard (1) · Daiichi Sankyo Co., Ltd. (1) · Five Prime Therapeutics, Inc. (1) · Nantes University Hospital (1) · Novartis Pharmaceuticals (1) · Plexxikon (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · SynOx Therapeutics Limited (1)
United States (13) · Netherlands (11) · France (8) · Poland (8) · Italy (7) · United Kingdom (7) · Spain (6) · Canada (5) · Australia (4) · China (4) · Germany (3) · Switzerland (3) · Hungary (2) · South Korea (2) · Taiwan (2)
Dorothy Nguyen, MD (3) · Andrew J. Wagner, MD, PhD (1) · Jean Y Blay, Prof, MD (1) · Jean Yves Blay, PR (1) · Maitreyi Sharma, MD (1) · Yingfang Ao, Prof. (1)
PMID 33289960, PMID 27041409, PMID 29571946, PMID 31229240, PMID 32755241, PMID 33926503, PMID 35932628, PMID 36001000, PMID 36869793, PMID 37593881, PMID 38843860, PMID 39287124, PMID 41796601, PMID 42132251, PMID 42473802, PMID 42872549
2014 (1)